Skip to Content

Clopidogrel Acino

Active Substance: clopidogrel
Common Name: clopidogrel
ATC Code: B01AC04
Marketing Authorisation Holder: Acino AG
Active Substance: clopidogrel
Status: Withdrawn
Authorisation Date: 2009-07-28
Therapeutic Area: Peripheral Vascular Diseases Stroke Acute Coronary Syndrome Myocardial Infarction
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

    • Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease
    • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA)
    • ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy
    • Patients suffering from acute coronary syndrome.

The marketing authorisation for Clopidogrel Acino has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide